KORTUC Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $16.3M

  • Investors
  • 9

KORTUC General Information

Description

Developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy. The company develops hydrogen peroxide-based drugs delivered via a prefilled syringe, injected intratumorally before radiotherapy to make hypoxic tumors responsive to radiation by inactivating antioxidative enzymes, enabling medical professionals to control the radiated tumors and improve the efficacy of radiation therapy.

Contact Information

Website
kortuc.com
Formerly Known As
Kortuc Usa
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 214 Homer Avenue
  • Palo Alto, CA 94301
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 214 Homer Avenue
  • Palo Alto, CA 94301
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

KORTUC Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 05-Nov-2021 $16.3M Completed Clinical Trials - Phase 2
4. Early Stage VC 20-Sep-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 10-Jan-2019 Completed Clinical Trials - Phase 2
2. Early Stage VC 28-Dec-2017 $868K $1.75M Completed Clinical Trials - Phase 1
1. Seed Round 28-Feb-2017 $884K $884K Completed Clinical Trials - Phase 1
To view KORTUC’s complete valuation and funding history, request access »

KORTUC Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class C Preferred
Class B Preferred
Class A3 Preferred
Class A2 Preferred 1,633 $528.14 $528.14 1x $528.14 8.94%
Class A Preferred 2,380 $369.7 $369.7 1x $369.7 13.03%
To view KORTUC’s complete cap table history, request access »

KORTUC Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy. The company develops hydro
Biotechnology
Palo Alto, CA
5 As of 2024

Malvern, PA
 

Paris, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

KORTUC Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Galera Therapeutics Formerly VC-backed Malvern, PA
Nanobiotix Formerly VC-backed Paris, France
You’re viewing 2 of 2 competitors. Get the full list »

KORTUC Patents

  • 44

    Total Documents Applications and Grants

  • Total Patents Families

  • 26

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

KORTUC Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4166147-A1 Sensitiser for cancer treatment Pending 15-Jun-2020
JP-2022168328-A Sensitizer for anticancer therapy Pending 15-Jun-2020
US-20230330230-A1 Sensitiser for cancer treatment Pending 15-Jun-2020
EP-4166147-A4 Sensitiser for cancer treatment Pending 15-Jun-2020
JP-6651155-B1 Syringe and kit suitable for hydrogen peroxide solution Active 21-Jun-2019
To view KORTUC’s complete patent history, request access »

KORTUC Executive Team (2)

Name Title Board Seat
Kazuyuki Matsuda Co-Founder, Chief Executive Officer & Board Member
Seiko Kuroda General Manager & Head of Operations
To view KORTUC’s complete executive team members history, request access »

KORTUC Board Members (1)

Name Representing Role Since
Kazuyuki Matsuda KORTUC Co-Founder, Chief Executive Officer & Board Member
To view KORTUC’s complete board members history, request access »

KORTUC Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KORTUC Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
AXA Japan Corporation Minority
Irimajiri Group Corporation Minority
SBI Investment Venture Capital Minority
Pegasus Tech Ventures Corporate Venture Capital Minority
SPARX Group Company Holding Company Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

KORTUC FAQs

  • When was KORTUC founded?

    KORTUC was founded in 2015.

  • Who is the founder of KORTUC?

    Kazuyuki Matsuda is the founder of KORTUC.

  • Who is the CEO of KORTUC?

    Kazuyuki Matsuda is the CEO of KORTUC.

  • Where is KORTUC headquartered?

    KORTUC is headquartered in Palo Alto, CA.

  • What is the size of KORTUC?

    KORTUC has 5 total employees.

  • What industry is KORTUC in?

    KORTUC’s primary industry is Biotechnology.

  • Is KORTUC a private or public company?

    KORTUC is a Private company.

  • What is the current valuation of KORTUC?

    The current valuation of KORTUC is .

  • What is KORTUC’s current revenue?

    The current revenue for KORTUC is .

  • How much funding has KORTUC raised over time?

    KORTUC has raised $24.4M.

  • Who are KORTUC’s investors?

    AXA Japan, Irimajiri Group, SBI Investment, Pegasus Tech Ventures, and SPARX Group Company are 5 of 9 investors who have invested in KORTUC.

  • Who are KORTUC’s competitors?

    Galera Therapeutics and Nanobiotix are competitors of KORTUC.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »